Drugs / Glucose-dependent insulinotropic polypeptide (GIP)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05078255 | Jan 2022 → Jan 2025 | obesity disorder, type 2 diabetes mellitus | Asger Lund, MD | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glucose-dependent insulinotropic polypeptide (GIP) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05078255 ↗ |
| Known as | GIP | “the incretin hormone glucose-dependent insulinotropic polypeptide (GIP)” NCT05078255 ↗ |
| Action | Activate | “The contribution of GIP receptor activation to these effects remains unknown.” NCT05078255 ↗ |
| Route | Subcutaneous | “continuous subcutaneous infusions of GIP or placebo” PMID 42173109 ↗ May 2026 |